迈威生物(688062)
 
 
  日线
顶尖财经网欢迎您!
  K线
 
 最新动态
  投资评级

研究机构 评级日期 最新评级 上次评级
国信证券 2024-01-31 增持
中信建投 2023-12-16 买入
广发证券 2023-12-10 买入
华金证券 2023-12-06 买入
安信证券 2023-12-05 买入
  盈利预测
据迈威生物三季报分析:

  盈利能力维持稳定,主营获利能力保持稳定

  成长能力维持稳定,营利增速步入上升通道

  偿债能力有所削弱,财务杠杆风险加大

  运营能力维持稳定,资金占用情况严重恶化

  现金流能力维持稳定,销售占用资金的局面仍未改变

  财务数据
    截至第三季度实现净利润-6.77亿元,每股收益-1.68元。

    截至第三季度最新股东权益291415.27万元,未分配利润-337120.33万元。

    截至第三季度最新总资产445053.22万元,负债153637.94万元。

利润表
报告期2023-09-302023-06-302023-03-312022-12-31
营业总收入99,511,384.0489,961,372.074,039,353.8127,728,179.2
营业总成本775,388,223.53505,087,817.6245,010,406.95993,418,897.81
营业利润-675,112,139.5-414,357,391.95-240,899,700.58-958,139,313.1
利润总额-676,041,100.24-415,364,379.05-241,704,855.16-958,125,799.13
净利润-676,619,021.82-415,942,300.63-241,704,855.16-958,125,799.13
其他综合收益4,789,781.455,581,924.53-576,600.154,160,991.6
综合收益总额-671,829,240.37-410,360,376.1-242,281,455.31-953,964,807.53
资产负债表
报告期2023-09-302023-06-302023-03-312022-12-31
流动资产合计2,149,595,299.692,400,226,320.872,572,510,083.82,778,057,919.49
非流动资产合计2,300,936,850.962,250,370,604.962,081,030,312.81,841,417,306.44
资产总计4,450,532,150.654,650,596,925.834,653,540,396.64,619,475,225.93
流动负债合计511,472,300.09500,327,738.55499,865,574.3445,144,461.85
非流动负债合计1,024,907,127.59996,526,017.48853,493,340.24663,719,989.8
负债合计1,536,379,427.681,496,853,756.031,353,358,914.541,108,864,451.65
归属于母公司股东权益合计2,922,560,368.13,161,235,553.823,305,856,055.233,515,685,913.09
股东权益合计2,914,152,722.973,153,743,169.83,300,181,482.063,510,610,774.28
负债和股东权益合计4,450,532,150.654,650,596,925.834,653,540,396.64,619,475,225.93
现金流量表
报告期2023-09-302023-06-302023-03-312022-12-31
经营活动现金流入小计226,168,080.81196,178,040.44148,871,418.14228,655,241.29
经营活动现金流出小计788,626,939.35517,526,821.88301,543,548.39947,826,387.7
经营活动产生的现金流量净额-562,458,858.54-321,348,781.44-152,672,130.25-719,171,146.41
投资活动现金流入小计280,841,968.42228,302,234.8960,303,273.4882,156,187.72
投资活动现金流出小计732,547,641.13606,375,188.02315,063,627.11,484,958,896.96
投资活动产生的现金流量净额-451,705,672.71-378,072,953.13-254,760,353.7-602,802,709.24
筹资活动现金流入小计431,300,191.33382,688,698.3237,826,431.333,786,073,382.16
筹资活动现金流出小计102,801,617.4589,480,353.0567,543,090.6470,263,253.79
筹资活动产生的现金流量净额328,498,573.88293,208,345.25170,283,340.693,715,810,128.37
汇率变动对现金及现金等价物的影响5,468,826.231,987,278.08-1,085,593.492,263,809.44
现金及现金等价物净增加额-680,197,131.14-404,226,111.24-238,234,736.752,396,100,082.16
期末现金及现金等价物余额1,809,447,557.542,085,418,577.442,251,409,951.932,489,644,688.68
  主营收入+营业利润
 
  净利润+每股收益
  股东权益+未分配利润
 
  总资产+负债
  投资要点

    截至第三季度实现净利润-6.77亿元,每股收益-1.68元。

    截至第三季度最新股东权益291415.27万元,未分配利润-337120.33万元。

    截至第三季度最新总资产445053.22万元,负债153637.94万元。

利润表
报告期2023-09-302023-06-302023-03-312022-12-31
营业总收入99,511,384.0489,961,372.074,039,353.8127,728,179.2
营业总成本775,388,223.53505,087,817.6245,010,406.95993,418,897.81
营业利润-675,112,139.5-414,357,391.95-240,899,700.58-958,139,313.1
利润总额-676,041,100.24-415,364,379.05-241,704,855.16-958,125,799.13
净利润-676,619,021.82-415,942,300.63-241,704,855.16-958,125,799.13
其他综合收益4,789,781.455,581,924.53-576,600.154,160,991.6
综合收益总额-671,829,240.37-410,360,376.1-242,281,455.31-953,964,807.53
资产负债表
报告期2023-09-302023-06-302023-03-312022-12-31
流动资产合计2,149,595,299.692,400,226,320.872,572,510,083.82,778,057,919.49
非流动资产合计2,300,936,850.962,250,370,604.962,081,030,312.81,841,417,306.44
资产总计4,450,532,150.654,650,596,925.834,653,540,396.64,619,475,225.93
流动负债合计511,472,300.09500,327,738.55499,865,574.3445,144,461.85
非流动负债合计1,024,907,127.59996,526,017.48853,493,340.24663,719,989.8
负债合计1,536,379,427.681,496,853,756.031,353,358,914.541,108,864,451.65
归属于母公司股东权益合计2,922,560,368.13,161,235,553.823,305,856,055.233,515,685,913.09
股东权益合计2,914,152,722.973,153,743,169.83,300,181,482.063,510,610,774.28
负债和股东权益合计4,450,532,150.654,650,596,925.834,653,540,396.64,619,475,225.93
现金流量表
报告期2023-09-302023-06-302023-03-312022-12-31
经营活动现金流入小计226,168,080.81196,178,040.44148,871,418.14228,655,241.29
经营活动现金流出小计788,626,939.35517,526,821.88301,543,548.39947,826,387.7
经营活动产生的现金流量净额-562,458,858.54-321,348,781.44-152,672,130.25-719,171,146.41
投资活动现金流入小计280,841,968.42228,302,234.8960,303,273.4882,156,187.72
投资活动现金流出小计732,547,641.13606,375,188.02315,063,627.11,484,958,896.96
投资活动产生的现金流量净额-451,705,672.71-378,072,953.13-254,760,353.7-602,802,709.24
筹资活动现金流入小计431,300,191.33382,688,698.3237,826,431.333,786,073,382.16
筹资活动现金流出小计102,801,617.4589,480,353.0567,543,090.6470,263,253.79
筹资活动产生的现金流量净额328,498,573.88293,208,345.25170,283,340.693,715,810,128.37
汇率变动对现金及现金等价物的影响5,468,826.231,987,278.08-1,085,593.492,263,809.44
现金及现金等价物净增加额-680,197,131.14-404,226,111.24-238,234,736.752,396,100,082.16
期末现金及现金等价物余额1,809,447,557.542,085,418,577.442,251,409,951.932,489,644,688.68
  十大流通股东
十大流通股东 报告期:2023-09-30
股东名称 持股数量(万股) 占总股本比例(%) 上期持股变化(万股)
海南拾玉私募基金管理有限公司-苏州永玉股权投资合伙企业(有限合伙)1542.457.63-190.25
吴军1107.745.48-247.95
苏鑫664.293.2944.76
深圳市东方富海创业投资管理有限公司-深圳富海股投邦七号投资企业(有限合伙)610.093.02-193.41
海通创新证券投资有限公司495.002.450.00
方正和生投资有限责任公司-安徽和壮高新技术成果基金合伙企业(有限合伙)454.522.25-19.69
中国农业银行股份有限公司-鹏华医药科技股票型证券投资基金411.712.0434.56
中国建设银行股份有限公司-富国精准医疗灵活配置混合型证券投资基金384.131.90384.13
香港中央结算有限公司372.061.84372.06
渤海银行股份有限公司-中信建投医改灵活配置混合型证券投资基金355.001.76355.00
  主力控盘
  公司简介
迈威生物 所属地域: 上海市 涉及概念: 沪股通,创新药,新冠治疗,重组蛋白,生物医药,融资融券
主营业务: 从事生物科技领域内的技术开发、技术咨询、技术服务、技术转让,技术推广服务,自有设备租赁,从事货物及技术的进出口业务。【依法须经批准的项目,经相关部门批准后方可开展经营活动】
上市日期: 2022-01-18 每股净资产: 7.31元 每股收益: -1.68元 净利润: -6.73亿元 净利润增长率: 2.76%
营业收入: 1.00亿元 每股现金流: -1.41元 每股公积金: 14.73元 每股未分配利润: -8.44元 总股本: 4.00亿 流通股: 2.01亿
以上信息为合作方、加盟公司及会员收集,本站不拥有版权,版权归原作者所有,所载文章、数据仅供参考,据此操作,风险自负。

中 华 顶 尖 财 经 -- 中 华 顶 尖 网 络 信 息 服 务 中 心